BCRF-funded teams from Dana-Farber, Brigham & Women's, and Children's Hospital identify potential marker to predict effectiveness of platinum-based chemotherapies for triple negative breast cancers
Dr. Andrea L. Richardson with co-BCRF grantees, Drs. Zhigang C. Wang and J. Dirck Iglehart
Lead author and BCRF grantee, Dr. Andrea L. Richardson
(Dana-Farber Cancer Institute), published results from two studies to understand the use of platinum-based chemotherapies in treating 28 women diagnosed with triple negative breast cancer. The study found that the treatment effects could be analyzed by the activity of certain chromosomes that prevent the cancer cells from repairing their DNA. Some triple negative breast cancers have been associated with mutations in the BRCA (breast cancer susceptibility) genes.
The study was conducted by a group of researchers headed by Dr. Richardson and included fellow BCRF grantees at Harvard-affiliated centers in Boston: Drs. Judy E. Garber, J. Dirk Iglehart, Zoltan Szallasi, Nadine Tung, and Zhigang C. Wang.